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ISSObjective(s): There is limited information on full-length genome sequences and the
early evolution of transmitted HIV-1 subtype C viruses, which constitute the majority of
viruses spread in Africa. The purpose of this study was to characterize the earliest
changes across the genome of subtype C viruses following transmission, to better
understand early control of viremia.
Design: We derived the near full-length genome sequence responsible for clinical
infection from five HIV subtype C-infected individuals with different disease pro-
gression profiles and tracked adaptation to immune responses in the first 6 months
of infection.
Methods: Near full-length genomes were generated by single genome amplification
and direct sequencing. Sequences were analyzed for amino acid mutations associated
with cytotoxic T lymphocyte (CTL) or antibody-mediated immune pressure, and for
reversion.
Results: Fifty-five sequence changes associated with adaptation to the new host were
identified, with 38% attributed to CTL pressure, 35% to antibody pressure, 16% to
reversions and the remainder were unclassified. Mutations in CTL epitopes were most
frequent in the first 5 weeks of infection, with the frequency declining over time with the
decline in viral load. CTL escape predominantly occurred in nef, followed by pol and
env. Shuffling/toggling of mutations was identified in 81% of CTL epitopes, with only
7% reaching fixation within the 6-month period.
Conclusion: There was rapid virus adaptation following transmission, predominantly
driven by CTL pressure, with most changes occurring during high viremia. Rapid escape
and complex escape pathways provide further challenges for vaccine protection.
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508 AIDS 2013, Vol 27 No 4IntroductionEarly host selective pressures drive genetic diversification
of the transmitted HIV and potentially influence the
course of disease. In heterosexual infection, it is estimated
that approximately 80% of individuals are infected with a
single virus or virus-infected cell [1,2]. Vaccines that do
not block the establishment of this initial infecting virus
will need to target the early diversifying virus and thus an
understanding of early viral evolution is important. The
frequency and speed at which the transmitted virus
changes in response to host immune pressures are of key
interest to vaccine immunogen design as these provide
insights into its strengths and vulnerabilities.
Recent methodologies using single genome amplification
(SGA) applied to individuals with acute HIV-1 infection
have enabled identification of the sequence of trans-
mitted/founder (t/f) full-length viral genomes [1,3,4].
This approach uses mathematical modeling to derive the
sequence of the virus(es) responsible for productive
clinical infection, and was proven in the simian
immunodeficiency virus (SIV) model wherein the
derived t/f was identical, or differed by a few nucleotides,
to the virus in the inocula [5].
Using this approach, early evolutionary changes following
transmission in three subtype B infections from the USA
have been mapped [3]. No longitudinal studies elucidat-
ing early evolution in full-length subtype C genomes have
been reported despite subtype C being the dominant
subtype both globally and in southern Africa where large
vaccine and microbicide trials take place [6,7]. Studies in
different population settings are essential given that
differences in host genetics influence viral evolution [8].
The transmitted virus encounters immune selective
pressures almost immediately following infection. Cyto-
toxic T lymphocyte (CTL) and neutralizing antibody
pressure are the proven driving forces for viral
diversification [9–16]. Evidence of CTL pressure on
the viral genome has been identified in the very first
weeks of subtype B and C infection [1–3,17–23], and
CTL activity has been associated with control of viremia
early in infection [24–26]. Most recently, a subtype B
full-length genome study using mathematical modeling
to determine the killing rate of CTL during acute viremia
suggested that these cells have a role in controlling peak
viremia [21].
In this study, we investigated changes observed across the
genomes of t/f subtype C viruses from five heterosexually
infected women with differing disease progression
profiles. We extrapolated the near full-length genome
sequence of the t/f viruses and quantified genetic
mutations associated with positive selection from humoral
and cellular immune pressures over the first 6 months
following infection.pyright © Lippincott Williams & Wilkins. UnauthoMethods
Study participants
Samples were obtained from the Centre for the AIDS
Program of Research in South Africa (CAPRISA) 002
Acute Infection cohort (Durban, South Africa) [27]. Date
of infection was estimated as the midpoint between last
negative and first positive HIVantibody test and as 14 days
prior for individuals who were RNA positive/antibody
negative. Human leukocyte antigen (HLA) A, B and C
types were determined using four-digit high-resolution
HLA typing as described [28]. The study was approved
by the Universities of Cape Town, Witwatersrand and
KwaZulu Natal.
PCR amplification and sequencing
RNA was extracted from 200–400 ml plasma using the
Qiagen Viral RNA Mini Kit (Qiagen, Valencia,
California, USA) and reverse transcribed to cDNA using
superscript III reverse transcriptase and Oligo(dT)20
(Invitrogen, GmbH, Karlsruhe, Germany). SGA [4] and
sequencing of near full-length genome amplicons was
done using Expand Long Template Taq (Roche
Diagnostics, Rotkreuz, Switzerland) as reported [4] with
primers described by Rousseau et al. [29] optimized for
subtype C. Sequences less than 6000 bp were excluded.
Salazar-Gonzalez et al. [3] attributed one to five
ambiguities within a genome obtained at less than 20%
PCR positivity predominantly to PCR Taq error. We
accepted amplicons obtained at less than 66% positivity
with up to six ambiguities. Targeted epitope sequencing
was done following gene-specific limiting dilution PCR.
Gag and nef clones were generated using limiting dilution
PCR and the pGEM-T Easy system as described [30].
Env SGA was described previously [4]. All products were
directly sequenced using the ABI 3000 genetic analyzer
(Applied Biosystems, Foster City, California, USA) and
BigDye terminator reagents.
Sequence analysis
Analyses performed were sequence alignments, amino
acid identity and frequency plots and consensus sequence
derivation (BioEdit version 7.0.8.0 [31]); subtyping
(REGA HIV Subtyping Tool; http://dbpartners.stanfor-
d.edu/RegaSubtyping/); phylogenetic and pairwise
DNA distance analyses (Mega 4 [32]); Highlighter plots
(http://www.hiv.lanl.gov/content/sequence/HIGHLIG
HT/highlighter); CTL epitope prediction (Epitope
Location Finder (ELF) (http://www.hiv.lanl.gov/con-
tent/sequence/ELF/epitope_analyzer) and NetMHCpan
2.2 (http://www.cbs.dtu.dk/services/NetMHCpan)[33]);
Hypermut detection of APOBEC hypermutation
(http://www.hiv.lanl.gov/content/sequence/HYPER
MUT/hypermnut.html); Shannon entropies (Entropy
One; http://www.hiv.lanl.gov/content/sequence/ENT
ROPY/entropy_one) and mapping of functionally/
structurally relevant genome regions (http://www.
hiv.lanl.gov/content/sequence/HIV/MAP/landmark). Arized reproduction of this article is prohibited.
Transmitted subtype C HIV-1 rapid adaptation Abrahams et al. 509high average Shannon entropy score was taken as more
than 0.25 as described by Bansal et al. [34] for variable HIV
proteins. Where an optimal epitope (9–11-mer) has not
yet been described, the entropy of an 18-mer peptide
encompassing the mutating region was used.
Time to most recent common ancestor (MRCA) was
determined using Bayesian Evolutionary Analysis
Sampling Trees (BEAST) v1.4.7 [35,36] as described
previously [1,2]. A relaxed (uncorrelated exponential)
molecular clock with general time-reversible substitution
model, mean of 2.16 105 substitutions per site per
generation with rates unlinked across codon sites [37] and
gamma distribution with four categories and a proportion
of invariant sites was used.
Known HLA class I restricted epitopes or class I HLA-
associated polymorphisms were identified using the Los
Alamos HIV Molecular Immunology 2008 Compen-
dium (http://www.hiv.lanl.gov/content/immunology/
compendium.html) and Matthews et al. [38]. Subtype
C database alignments were obtained from the Los
Alamos HIV database (http://www.hiv.lanl.gov/com
ponents/sequence/HIV/).
Positive selection and statistical analysis
Nonsynonymous to synonymous substitution (dN/dS)
rate ratios per codon site were estimated using the
MG94xHKY85 codon model [39]. We allowed dS to
vary across codon sites and employed the Dual model
which takes into account that dS may vary independently
of dN [40]. Models were implemented within HyPhy
[41] and ensured that correct phylogenetic relationships
were used for regions separated by recombination
breakpoints [42].
Categorical statistical tests were carried out using the
Fisher’s exact two-tailed test (http://www.graphpad.
com/quickcalcs).Results
This study characterized virus evolution in five subtype
C-infected women recruited 2–5 weeks following
transmission. These women were selected based on
infection with a single transmitted/founder virus [2] and
clinical disease progression profile (Table 1). One woman
was classified as a viremic controller (CAP45; viral loads
consistently <2000 copies/ml and CD4 cell counts
>350 cells/ml in the absence of antiretroviral therapy)
[43], two as rapid progressors (CAP63 and CAP210; viral
loads >100 000 copies/ml and CD4 cell counts
<350 cells/ml on consecutive visits within the first year
of infection) [23,44], and two as intermediate progressors
(CAP85 and CAP239; not fitting either controller or
rapid status) (Fig. 1). A total of 112 near full-lengthCopyright © Lippincott Williams & Wilkins. Unautgenomes were generated, with an average of nine at
screening per enrolment (2–5 weeks after infection), six
at 3 months (11–13 weeks after infection) and nine at
6 months (22–29 weeks after infection). No sequences
could be generated at 6 months for viremic controller
CAP45 due to low viral loads. Additional sequences (half-
genome, SGA and clonal) were generated from various
time points ranging from 2 to 117 weeks after infection
(Table 1).
Derivation of transmitted/founder virus
sequences
All sequences were classified as subtype C along the entire
length of the genome. Mean intraparticipant DNA
distances ranged from 0.008 to 0.25% (median 0.03%) at
the first time point and mean number of days since
MRCA ranged from 18 to 53 days (Table 1), indicating
limited sequence diversification since transmission
(see Fig. S1, Supplemental Digital Content 1, http://
links.lww.com/QAD/A282, illustrating intraparticipant
sequence diversity in a Neighbour-Joining tree). The t/f
sequences were defined as the consensus of sequences from
the earliest time point where all genes had an intact open
reading frame and no ambiguities [3]. Although CAP63
and CAP85 were classified as infected with a single t/f
variant based on env [2], we identified a minor early variant
in each (not detected at later time points) which, in both
cases, differed from the derived t/f at five nucleotide
positions, suggesting that these individuals may each have
been infected with two very closely related variants.
The majority of early genetic changes are due to
cytotoxic T lymphocyte pressure or reversion
Using longitudinal near full-length genome and env
screening/enrolment SGA sequences, viral evolution
from the t/f was analyzed for evidence of immune escape
or reversion. Substitutions from high-frequency/con-
sensus to lower frequency/nonconsensus amino acids
within or adjacent to known class I HLA-restricted
epitopes, or corresponding to known HLA-associated
polymorphisms, were classified as CTL pressure [16,19,
45,46]. Mutations within the hypervariable loops and
potential N-linked glycosylation sites (PNGSs) in env
were classified as antibody pressure [9]. Mutations from
low/nonconsensus to higher frequency/consensus subtype
C amino acids within CTL epitopes not restricted by the
participants HLAwere classified as reversion of transmitted
CTL escape mutations [16,45,46]. In addition, clustered
mutations within amino acid 9-mers, previously reported
to be associated with immune selection [18], or single
amino acid mutations persisting to fixation and corre-
sponding to sites under positive selection were identified as
putative immune escape.
In viruses from the five women, immune pressure was
identified in 55 genome regions (see Figs S2–S6,
Supplemental Digital Content 2, http://links.lww.
com/QAD/A282, which illustrate genome regionshorized reproduction of this article is prohibited.
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Fig. 1. Clinical and immune selection profiles for each of the five women illustrated with viral load and CD4 cell count graphs.
The number of epitopes/genome regions identified as under putative cytotoxic T-lymphocyte pressure (black squares) and
antibody pressure (black triangles) are illustrated for approximate periods after infection of 0–5 weeks (pale blue shaded region),
5–12 weeks (darker blue shaded region) and 12–29 weeks (gray shaded region). The dashed gray box is used for participant
CAP45 as the black square represents an epitope which may have mutated anywhere between 12 and 65 weeks after infection.
Time of first detection of autologous neutralizing antibodies is indicated by dashed red lines.
Co
512 AIDS 2013, Vol 27 No 4under immune pressure): 21 were classified as under CTL
pressure (Table 2), 19 under antibody pressure (Table 3),
nine as reversion (see Table S1, Supplemental Digital
Content 3, http://links.lww.com/QAD/A282, which
tabulates genome regions undergoing reversion) and
further six regions contained mutations (clustered within
amino acid 9-mers or single persisting to fixation in sites
under positive selection) which did not conform to
criteria described for CTL or antibody pressure or
reversion (Table 3). Identification of regions under
immune pressure was supported by selection analysis (for
which gag, env and nef supplemental sequences were
included), which found a total of 55 sites under positive
selection (dN/dS >1) of which 84% (46/55) were
situated within genome regions identified as under
immune pressure (see Tables 2 and 3; Table S1, Supple-
mental Digital Content 3 and Figs S2–S6, Supplemental
Digital Content 2, http://links.lww.com/QAD/A282,
which illustrate positive selection sites corresponding to
genome regions under immune pressure). The majority
of positively selected sites were identified in env (n¼ 30),
followed by gag (n¼ 9), pol (n¼ 7), nef (n¼ 5), rev (n¼ 3)
and tat (n¼ 1). APOBEC-mediated G to A hypermuta-
tion was identified in 24% (13/55) of regions under
immune selection.
Of the mutating genome regions associated with CTL
pressure, 19 spanned known CTL epitopes, and two
spanned predicted epitopes (Table 2). The highest
frequency of CTL-driven mutations was located in nef
(even when normalizing for amino acid length) (n¼ 6),
followed by pol and env (n¼ 4), gag and vif (n¼ 2) and
finally rev, tat and vpr (n¼ 1) (Fig. 2a). Reversion was
identified most frequently in vpu (n¼ 3) followed by gag,
env and nef (n¼ 2) (see Table S1, Supplemental Digital
Content 3, http://links.lww.com/QAD/A282).
Cytotoxic T lymphocyte escape is most frequent
in acute infection
We supplemented near full-length genomes with sub-
genomic (gag, env, nef and targeted epitope) sequence data
to better elucidate timing of mutations associated with
CTL pressure and escape. The majority of mutating
epitopes was identified within the first 5 weeks of
infection in structural genes gag, pol, env and nef (Figs 1
and 2b). The earliest of these was identified at 2 weeks
postinfection in the gag HLA B58 : 01 restricted TW10
epitope; and the nef HLA B45 : 01 restricted EV11
epitope. The frequency of mutation associated with
escape slowed over time with an initial 1.6 total escapes
per week for the first 5 weeks of infection, to 0.9 escapes
per week between 5 and 12 weeks postinfection, and 0.4
escapes per week between 12 and 29 weeks postinfection
(Fig. 2b).
Of the 19 regions of env with changes in hypervariable
loops and PNGSs, mutations in seven (37%) arose in the
first 5 weeks of infection (Fig. 1 and Table 3). Since firstpyright © Lippincott Williams & Wilkins. Unauthodetection of autologous neutralizing antibodies (nAb) for
the women in this study ranged from 9 to 46 weeks
[44,47] (Fig. 1), these early changes are unlikely to be the
result of nAb pressure. However, in one instance, early
mutating sites in V5 of participant CAP45 corresponded
to sites where neutralization escape mutations (K460D
and D462G) were identified later in infection (see
Table 3) [44].
Finally, of the nine reversions identified, four occurred in
the first 5 weeks of infection and the remaining between
13 and 29 weeks postinfection (data not shown).
Shuffling and toggling of amino acid mutations
Shifting of mutations between different positions within
an epitope (shuffling) or between different amino acids at
the same position (toggling) was observed in 81% (17/21)
of mutating CTL epitopes (see Table 2 and Table S2,
Supplemental Digital Content 4, http://links.lww.com/
QAD/A282, illustrating shuffling and toggling in a Nef
epitope). For four of the five participants, the number of
mutant variants per CTL epitope increased over the
6 months of infection after which a plateau or decrease
was seen owing in part to eventual fixation of escape
mutants (Fig. 2c).
Twelve of the 17 CTL epitopes with shuffling/toggling
mutations corresponded to subtype C database epitopes
with high Shannon entropy (scores >0.25 [34]).
Shuffling/toggling was however not more frequent in
epitopes corresponding to high-entropy regions than in
more conserved regions (P¼ 0.25). We investigated
whether mutational shuffling/toggling was due to
mutations arising in structurally or functionally essential
sites, which when altered may abrogate efficient RNA
folding or alter protein structure and function. We
therefore compared the proportion of epitopes with
shuffling/toggling in functionally or structurally relevant
sites with the proportion in sites with no currently known
functional or structural significance. We found no signi-
ficant difference between the two categories (P¼ 0.53),
even when including the six genome regions under
unclassified immune pressure (P¼ 0.28).
Immune pressure, sequence diversification and
disease progression
To determine whether rate of genetic diversification from
t/f sequences differed with different disease progression
profiles, we compared gene-specific tree lengths using
sequences from the first 3 months of infection. No
significant differences between rates of diversification
were found (data not shown). Furthermore, no significant
association between number of genome regions under
immune pressure and viral load over time was identified
(data not shown); possibly owing to low participant
numbers.rized reproduction of this article is prohibited.
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Time of first mutation in
hypervariable loop or PNGS
(range) (weeks)
CAP45 Gp120 LTRDGGKTDRNDTEIFRP 454–470 Antibody 0–2
CAP63 Gp120 QEIVLENVIENFNMWKND 82–99 Antibody 5–11
Gp120 LTPLCVTLNCANANITKN 122–139 Antibody 11–29
Gp120 MIGEIKNCSFNATTELRD 147–167 Antibody 2–5
Gp120 LNNNRSNENSYILINCNS 184–198 Antibody 0–2
Gp120 IVHFNQSVKIVCARPHNN 285–302 Antibody 11–29
Gp120 IRQAHCNISKTQWNTTLE 326–343 Antibody 11–29
Gp120 FNSTYMPNGIHIPNGASEVIT 396–415 Antibody 2–5
Gp41 LWSWFNISHWLWYIRIFI 158–147 Antibody 11–29
Gp41 IEEEGGEQDNSRSIRLVS 222–239 Antibody 5–11
CAP85 Gp120 DIVPLNNDIGNYSEYRLI 180–194 Antibody 5–13
Gp120 IVHLNHSVKIVCTRPGNN 285–302 Antibody 0–5
Gp120 IRQAHCNISKAEWNNTLE 326–343 Antibody 13–29
Gp120 GSSTTTNGSSPITLPCRI 404–420 Antibody 0–5
Gp120 RPGGGDMKDNWRSELYKY 469–486 Unclassified 0–5
Nef GVGAASQDLGKYGALTSS 29–46 Unclassified 0–5
CAP210 Pol FFRENLAFPEGEARELPS 1–18 Unclassified 12–16
Gp120 ICSFNATTELRDKKKKEY 156–173 Antibody 5–12
Gp120 FNSTHNSTDSTVNSTDST 391–409 Antibody 5–12
Gp120 ITCISNITGLLLTRDGGE 443–460 Antibody 22–26
Nef SLHGMEDTEREVLQWKFD 169–186 Unclassified 5–12
CAP239 Gag SNPSGPKRPIKCFNCGRE 382–399 Unclassified 2–5
Rev GRPAEPVPFQLPPIERLH 65–82 Unclassified 2–5
Gp120 DIIIRSQNILDNTKTIIV 269–286 Antibody 2–5
Gp120 GLLLTWDGGDSKENKTRH 451–467 Antibody 11–22
PNGS, potential N-linked glycosylation site.
aBold amino acids indicate sites undergoing mutation; underlined amino acids indicate sites evolving under positive selection; highlighted amino
acids indicate sites mutating to result in a change within, or gain/loss of a potential N-linked glycosylation site gain/loss (NXS/Tx, where x is not
Proline).Discussion
Design of a globally relevant HIV-1 vaccine requires an
understanding of transmitted viruses and their early
immune adaptation in different populations. Here, we
report the first study to comprehensively identify and
classify the earliest changes to subtype C transmitted/
founder full-length genome viruses. We provide a
detailed analysis of the timing, frequency and patterns
of these changes in five women with differing clinical
disease progression. The predominant and earliest host
selective pressure was from cytotoxic T lymphocytes.
Despite increasing breadth of CTL responses over time
[23], the frequency of mutations associated with CTL
escape declined as viral load declined. We show that
complex mutational pathways are used to escape in the
majority of epitopes.
We predicted that CTL pressure, or reversion of
transmitted escape, accounted for the majority (54%)
of changes across the genome, reaffirming the importance
of this response in early infection. Supporting our
predictions, autologous peptide screening using IFN-g
ELISPOT in three of the five participants confirmed all
nine epitopes predicted for these individuals (Liu et al., in
press). A further four of the 21 epitopes were likewise
confirmed to be responsive (Liu et al., unpublished data).
The remaining eight were not confirmed either due topyright © Lippincott Williams & Wilkins. Unauthopoor cell quality or screening after escape had already
occurred. Mutations associated with CTL escape
occurred earliest in gag and most frequently in nef,
although this was likely influenced by the fact that three of
the five individuals were HLA B45 : 01 positive and
targeted the same nef epitope. A further 35% of changes
were associated with antibody pressure. We could not
classify 11% of changes which may be associated with
novel CTL epitopes (possibly in alternate reading frames
[48,49]), compensation of escape, changes in antigen
processing, CD4þ T-cell pressure, natural killer (NK) cell
pressure [50], nonneutralizing binding antibody activity,
antibody-dependent cellular cytotoxicity (ADCC), viral
fitness or evolutionary drift/hitchhiking. One unclassi-
fied mutating region in pol of participant CAP210 was
subsequently found to be responsive by IFN-g ELISPOT
and may represent a novel CTL epitope (Liu et al., in
press). Another mutating region in nef of CAP210
corresponded to a known HLA-DR CD4þ T-cell
epitope; however, it was not restricted by the participants’
HLA-DR (data not shown).
Three findings from this study illustrate the immense
pressure the virus is under following infection. First, in
these five women, escape was rapid and occurred at high
frequency in acute infection (<5 weeks postinfection),
with a four-fold reduction in the number of escapes per
week over the 6-month period. Seventy percent of earlyrized reproduction of this article is prohibited.











































































































Fig. 2. Frequency, timing and complexity of putative cytotoxic T lymphocyte escape in the first 6 months of infection. (a) Total
number of putative escapes per gene and per 100 amino acids (AAs). (b) Total number of putative escapes per week. (c) Total
number of variants per CTL epitope over time for each of the five women. CTL, cytotoxic T lymphocyte.escape (<12 weeks postinfection) occurred in high-
entropy locations compared with only 33% after 12 weeks.
These observations, although not statistically significant
due to low sample size, consolidate reports that strong
CTL pressure and rapid escape prevail early in infection
[21,51] and that epitopes with higher entropy escape
faster than more conserved epitopes [52]. Thus, the
observed reduction in mutations associated with CTL
escape later in infection seen in these women may be
associated with targeting of epitopes that escape slowly.
Second, the pathway to CTL escape is complex, with this
study showing an unprecedented level (81%) of genome
regions under CTL pressure with mutations shifting
between different amino acid sites or between different
amino acids at the same site resulting in late or no fixation
over the period investigated. A recent study proposed that
initial mutations are replaced by secondary mutations
which are less costly to the virus with respect to its
survival [53]; however, we found no statistical support for
more frequent shuffling/toggling in virus regions of
structural or functional importance. It may be that this
pattern of variation is seen simply because these regions of
the genome are able to tolerate multiple changes
(supported by the fact that 71% of the epitopes with
shuffling/toggling corresponded to high-entropy data-
base epitopes). Alternatively, fixation may only occurCopyright © Lippincott Williams & Wilkins. Unautonce mutations are introduced into sites facilitating
complete escape as postulated in a detailed study of one
participant by Henn et al. [54].
Third, and perhaps surprisingly since neutralizing
antibody pressure typically emerges some weeks or
months after infection [9,55,56], we identified escape
patterns typically associated with antibody pressure as
early as 2 weeks postinfection. Autologous nAb response
data for these five participants indicate the earliest
response to have arisen at 9 weeks postinfection [44].
These early changes could possibly be attributed to
reversion of antibody escape mutations in the donor, early
stochastic changes, nonneutralizing binding antibody
activity, ADCC, env fitness or as very recently reported in
a subtype B study by Bar et al. [57], may in fact be a result
of early low level neutralizing antibody responses from
which the virus escapes. We saw evidence for this in V5 of
CAP45 wherein early changes corresponded to sites
where nAb escape later in infection was confirmed in this
participant [44].
When examining participant sequence data in the context
of disease progression, we found no significant differences
in early virus sequence diversification between individ-
uals in our study. However, larger studies would be
needed to evaluate the role of CTL escape in diseasehorized reproduction of this article is prohibited.
Co
516 AIDS 2013, Vol 27 No 4progression. Recent studies revealed that clinical disease
profiles are heritable in donor–recipient pairs [58,59] and
that viral genotype can be a determinant of viral load
set point [60]. Furthermore, transmission of a virus
harboring a mutation with a fitness cost can also
contribute to viral control [28,61]. We observed that
viremic controller CAP45 was infected with a virus
harboring mutations flanking the B57/58 Gag TW10
and ISW9 epitopes previously reported to be associated
with disease control [28]. It is worth mentioning that the
two rapid progressors in this study were HLA-B (CAP63)
and HLA-A, HLA-B and HLA-C (CAP210) homo-
zygous. HLA homozygosity has previously been associ-
ated with poor clinical outcome [62].
Numerous CTL studies propose stable CTL epitopes that
escape slowly or late in infection due to high fitness costs
to be good vaccine targets [21,38,51]. This study suggests
that the process of immune escape holds greater
complexities which vaccine design strategies will need
to take into account. Frequent and persistent shuffling
and toggling of mutations within targeted epitopes may
indicate high levels of epitope instability early in
infection. Early APOBEC-mediated hypermutation,
identified in more than a quarter of genome regions
under putative immune pressure in this study, represents
an efficient mechanism of CTL escape [22]. Not to be
discounted is the unclassified 11% of genome changes
which demonstrate that much more is at play very early in
infection, possibly such as pressure from NK cells which
has recently been emphasized [50]. These additional
forces likely play a significant role in shaping the
early virus.
Our findings provide novel data on the dynamic interplay
between virus and host very early in infection and the
complex pathways of escape in response to the earliest
immune pressures acting on transmitted/founder subtype
C viruses. These processes of immune adaptation are
likely to pose further challenges that vaccines will need to
overcome. Furthermore, this study demonstrates the
highly sensitive nature of viral sequencing as a tool for the
identification and characterization of early immune
selective pressures that mould early HIV-1 evolution.
Examining early host–virus interactions in the context of
disease progression will enable us to identify those
changes to the virus which are associated with better
disease outcome and may therefore be incorporated into
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